CHRS Stock Analysis: Buy, Sell, or Hold?
CHRS - Coherus Oncology, Inc. Common Stock
$1.52
0.06 (4.11%)
▲
5d:
+10.14%
30d:
-5.59%
90d:
-11.11%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When CHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CHRS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CHRS is currently trading at $1.52, which is considered fair relative to its 30-day fair value range of $1.41 to $1.58.
Technical Outlook: Technically, CHRS is in a strong uptrend. The price is approaching resistance at $1.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.80 (+413.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CHRS is in a strong uptrend. The price is approaching resistance at $1.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: CHRS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.80 (+413.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.41 -
$1.58
Company Quality Score
51/100
(HOLD)
Options IV Signal
32th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
87.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 32th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 413.2% below Wall St target ($7.80)
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.58
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.23
(15.2%)
Support & Resistance Levels
Support Level
$1.33
Resistance Level
$1.57
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$7.80
(+413.2%)
Revenue Growth (YoY)
62.0%
Earnings Growth (YoY)
-75.5%
Profit Margin
397.3%
Share & Embed Analysis
Last updated: June 24, 2026 5:21 PM ET
Data refreshes hourly during market hours. Next update: 6:21 PM
Data refreshes hourly during market hours. Next update: 6:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 61 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
